Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis

Thita Chiasakul; Christina R. Evans; Alex C. Spyropoulos; Gary Raskob; Mark Crowther; Adam Cuker

doi:10.1016/j.thromres.2019.10.027

Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis

Thita Chiasakul, Christina R. Evans, Alex C. Spyropoulos, Gary Raskob, Mark Crowther, Adam Cuker

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English
Pages (from-to)	58-61
Number of pages	4
Journal	Thrombosis Research
Volume	184
DOIs	https://doi.org/10.1016/j.thromres.2019.10.027
State	Published - Dec 2019
Externally published	Yes

Access to Document

10.1016/j.thromres.2019.10.027

Cite this

@article{3e2d28d5732747e0bfc05c2225c832ca,

title = "Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis",

author = "Thita Chiasakul and Evans, {Christina R.} and Spyropoulos, {Alex C.} and Gary Raskob and Mark Crowther and Adam Cuker",

note = "Funding Information: A.C. has served as a consultant for Genzyme and Synergy and his institution has received research support on his behalf from Alexion , Bayer , Novo Nordisk , Pfizer , Sanofi , Spark , and Takeda . A.C.S. has served as a consultant for Janssen, Bayer, Boehringer Ingelheim, and the ATLAS Group and has received research support from Janssen , Boehringer Ingelheim , and BMS/Pfizer . G.R. has served as a consultant for Anthos, Bayer Healthcare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer, Portola, and Tetherex. M.C. has served as a consultant and/or speaker for Shionogi, Alexion, Pfizer, Daiichi, Octapharma, BMS Canada, CSL Behring, Servier Canada, Diagnostica Stago, and Asahi Kasei; his institution has received research grants from LEO Pharma Research Foundation and the Heart and Stroke Foundation , and M.C. holds shares Alnylam. T.C. and C.R.C. have no disclosures. Funding Information: A.C. has served as a consultant for Genzyme and Synergy and his institution has received research support on his behalf from Alexion, Bayer, Novo Nordisk, Pfizer, Sanofi, Spark, and Takeda. A.C.S. has served as a consultant for Janssen, Bayer, Boehringer Ingelheim, and the ATLAS Group and has received research support from Janssen, Boehringer Ingelheim, and BMS/Pfizer. G.R. has served as a consultant for Anthos, Bayer Healthcare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer, Portola, and Tetherex. M.C. has served as a consultant and/or speaker for Shionogi, Alexion, Pfizer, Daiichi, Octapharma, BMS Canada, CSL Behring, Servier Canada, Diagnostica Stago, and Asahi Kasei; his institution has received research grants from LEO Pharma Research Foundation and the Heart and Stroke Foundation, and M.C. holds shares Alnylam. T.C. and C.R.C. have no disclosures.",

year = "2019",

month = dec,

doi = "10.1016/j.thromres.2019.10.027",

language = "English",

volume = "184",

pages = "58--61",

journal = "Thrombosis Research",

issn = "0049-3848",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients

T2 - A systematic review and meta-analysis

AU - Chiasakul, Thita

AU - Evans, Christina R.

AU - Spyropoulos, Alex C.

AU - Raskob, Gary

AU - Crowther, Mark

AU - Cuker, Adam

N1 - Funding Information: A.C. has served as a consultant for Genzyme and Synergy and his institution has received research support on his behalf from Alexion , Bayer , Novo Nordisk , Pfizer , Sanofi , Spark , and Takeda . A.C.S. has served as a consultant for Janssen, Bayer, Boehringer Ingelheim, and the ATLAS Group and has received research support from Janssen , Boehringer Ingelheim , and BMS/Pfizer . G.R. has served as a consultant for Anthos, Bayer Healthcare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer, Portola, and Tetherex. M.C. has served as a consultant and/or speaker for Shionogi, Alexion, Pfizer, Daiichi, Octapharma, BMS Canada, CSL Behring, Servier Canada, Diagnostica Stago, and Asahi Kasei; his institution has received research grants from LEO Pharma Research Foundation and the Heart and Stroke Foundation , and M.C. holds shares Alnylam. T.C. and C.R.C. have no disclosures. Funding Information: A.C. has served as a consultant for Genzyme and Synergy and his institution has received research support on his behalf from Alexion, Bayer, Novo Nordisk, Pfizer, Sanofi, Spark, and Takeda. A.C.S. has served as a consultant for Janssen, Bayer, Boehringer Ingelheim, and the ATLAS Group and has received research support from Janssen, Boehringer Ingelheim, and BMS/Pfizer. G.R. has served as a consultant for Anthos, Bayer Healthcare, BMS, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer, Portola, and Tetherex. M.C. has served as a consultant and/or speaker for Shionogi, Alexion, Pfizer, Daiichi, Octapharma, BMS Canada, CSL Behring, Servier Canada, Diagnostica Stago, and Asahi Kasei; his institution has received research grants from LEO Pharma Research Foundation and the Heart and Stroke Foundation, and M.C. holds shares Alnylam. T.C. and C.R.C. have no disclosures.

PY - 2019/12

Y1 - 2019/12

UR - http://www.scopus.com/inward/record.url?scp=85074504958&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2019.10.027

DO - 10.1016/j.thromres.2019.10.027

M3 - Letter

C2 - 31707152

AN - SCOPUS:85074504958

VL - 184

SP - 58

EP - 61

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -